• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Renvela (sevelamer carbonate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Renvela (sevelamer carbonate)

  • Profile

Profile

Contact Information

Contact: Sanofi-Aventis
Website: https://getrevela.com/

Currently Enrolling Trials

    Show More

    General Information

    Renvela contains sevelamer carbonate, a non-absorbed phosphate binding crosslinked polymer, free of metal and calcium. It contains multiple amines separated by one carbon from the polymer backbone. These amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding.

    Renvela is specifically indicated for the control of serum phosphorus in patients with chronic kidney disease on dialysis.

    Mechanism of Action

    Renvela’s amines exist in a protonated form in the intestine and interact with phosphate molecules through ionic and hydrogen bonding. By binding phosphate in the dietary tract and decreasing absorption, sevelamer carbonate lowers the phosphate concentration in the serum.

    Side Effects

    Adverse events associated with the use of Renvela may include, but are not limited to, the following:

    • Vomiting
    • Nausea
    • Diarrhea
    • Dyspepsia
    • Abdominal pain
    • Flatulence
    • Constipation

    Dosing/Administration

    Renvela is supplied as a tablet designed for oral administration. The recommended initial dose is as follows:

    Patients Not Taking a Phosphate Binde:
    Serum phosphorus >5.5 and <7.5 mg/dL: Renvela 800 mg one tablet three times daily with meals.
    Serum phosphorus ≥7.5 and <9.0 mg/dL: Renvela 800 mg two tablets three times daily with meals.
    Serum phosphorus ≥9.0 mg/dL Renvela 800 mg two tablets three times daily with meals.

    Patients Switching from Sevelamer Hydrochloride
    Sevelamer carbonate should be prescribed on a gram per gram basis. Further titration to the desired phosphate levels may be necessary. The highest daily dose of sevelamer carbonate studied was 14 grams in CKD patients on dialysis.

    Patients Switching from Calcium Acetate
    The dose schedule of Renvela should match the dose schedule of the current calcium acetate dose (i.e., if current calcium acetate dose is 1 tablet per meal, the Renvela dose should be 1 tablet per meal).

    Dose Titration for All Patients Taking Renvela
    The dose should be increased or decreased by one tablet per meal at two-week intervals, as necessary, with the goal of controlling serum phosphorus within the target range of 3.5 mg/dL to 5.5 mg/dL.

    Clinical Trial Results

    FDA approval of Renvela was based on a double-blind, active controlled, cross-over study in 79 hemodialysis patients with two eight-week treatment periods. Stage 5 CKD patients on hemodialysis were entered into a five-week sevelamer hydrochloride run-in period and received, in random order, sevelamer carbonate 800 mg tablets and sevelamer hydrochloride 800 mg tablets for eight weeks each, with no intervening washout. Study dose during the cross-over period was determined based on the sevelamer hydrochloride dose during the run-in period on a gram per gram basis. The phosphate levels at the end of each of the two cross-over periods were similar. Average actual daily dose was 6 g/day for both treatments.

    Additional Information

    For additional information regarding Renvela or elevated serum phosphorus in patients with chronic kidney disease on dialysis, please visit the Renvela web

    Approval Date: 2007-10-01
    Company Name: Genzyme
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing